Law firms Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business · 6 October 2016 · 1 min read Corporate and M&A Deal watch Linklaters Pinsent Masons Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this category‘The centre of gravity for Southeast Asia’ – why PE investment is making Singapore increasingly attractiveLaw firmsKate Peacock8 May 2026Revolving Doors: US firms lead hiring as White & Case, Cleary, McDermott build across EuropeLaw firmsEliza Winter8 May 2026Slaughters and Linklaters take the call as Vodafone buys CK Hutchison out for £4.3bnLaw firmsTheresa Hargreaves6 May 2026Ashurst EMEA energy and infrastructure M&A head set to join Vinson’s City baseLaw firmsWill Lewallen11 May 2026Latham and Davis Polk gear up for $2bn Lime IPOLaw firmsWill Lewallen11 May 2026Sidley sees exit of four-partner private equity team across NY and LondonLaw firmsWill Lewallen8 May 2026Dealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealLaw firmsAlex Ryan15 Jan 2024Dealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanLaw firmsAlex Ryan8 Dec 2023Deal Watch: activity powers on as Latham and A&O lead on $19bn energy joint ventureLaw firmsMegan Mayers9 Sep 2022